Swiss drugmaker Roche Holding AG (RHHBY) said Tuesday that RADIATE, the third study in Actemra's (tocilizumab) extensive multinational phase III development programme, successfully met its primary endpoint.
The study examined Actemra in combination with methotrexate in rheumatoid arthritis (RA) patients who had an inadequate response to anti-tumour necrosis factor therapy (anti-TNFs).
The study conducted in 498 patients with difficult-to-treat RA disease, showed that a greater proportion of patients treated with Actemra plus methotrexate, achieved a significant improvement in disease signs and symptoms (ACR scores3) following 24 weeks of treatment, compared to patients treated with placebo plus methotrexate.
"RADIATE's positive outcome further confirms the critical role of IL-6 in the pathophysiology of rheumatoid arthritis," said Urs Schleuniger, Business Director, Inflammation and Autoimmune Disease, Roche Pharmaceuticals. "These results add to the wealth of data being compiled ahead of the anticipated regulatory filing later this year," he added.
Subscribe to:
Post Comments (Atom)
1 comment:
Great information and important to continue to follow. With the emergence of Biologics for RA over the past years, this poses another chance at successful treatment for those hard to treat.
Additionally, with the issue of poor compliance to current self injectable therapies another infused treatment option can make for greater compliance as well as less anxiety due to less frequent treatment.
For more information you can go to www.bioplusrx.com and review updates via the newsletter or submit questions to an advisory board.
Patient assistance is also offered via www.arthritisrxassist.com
Post a Comment